The 340B Drug Pricing Program, created by Congress to extend federal resources and improve patient care, is under renewed scrutiny following the release of a new infographic by ADAP Advocacy. The infographic, part of the organization's ongoing 340B Project, reinforces the central message of a policy paper and commercial released earlier this year under the same name: "340B PROGRAM: The Glue That Should Hold Our Healthcare System Together."
At the heart of the issue is a striking paradox: even as 340B drug purchases soared above $100 billion in 2025 across more than 42,000 covered entities and over 32,000 pharmacies, charity care continues to decline year after year. The Affordable Care Act added requirements for hospitals to provide free care and financial aid to poor patients, but the data suggest those obligations are not being met. The new infographic connects the dots on the program's unfettered growth and how that growth is failing to deliver on the program's promise.
The implications are significant. The 340B program was designed to help safety-net providers stretch scarce federal resources and expand care to vulnerable populations. Instead, the infographic highlights hospitals' declining charity care, rising healthcare executive compensation, and exploding patient medical debt. These trends suggest that the program's benefits are increasingly flowing to large health systems and executives rather than to the patients it was intended to serve. As ADAP Advocacy's '340B Too Big To Fail' national advocacy campaign underscores, the program has become too large and too entrenched to ignore, yet its accountability mechanisms remain weak.
For policymakers, the infographic serves as a timely call to action. With 340B spending surpassing $100 billion, the program's fiscal footprint is enormous. If charity care is declining while executive pay and medical debt rise, the program may be subsidizing profits rather than patients. This could fuel legislative efforts to reform 340B eligibility, transparency, and reporting requirements. It also raises questions about whether covered entities are complying with ACA charity care mandates, and whether the federal government should tie 340B participation to measurable patient outcomes.
For patients and advocates, the infographic provides ammunition to demand greater oversight. ADAP Advocacy's mission is to promote and enhance AIDS Drug Assistance Programs and improve access to care for persons living with HIV/AIDS. The 340B program is a critical funding source for many HIV clinics and other safety-net providers. If the program's benefits are not reaching patients, those populations could face reduced access to life-saving medications and services.
The infographic can be downloaded online here. As the debate over healthcare costs and drug pricing intensifies, ADAP Advocacy's work ensures that the 340B program's original intent—to hold the healthcare system together for the most vulnerable—remains front and center.
